PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CML”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources
PubMedDate not supplied

Sometimes it really is appendicitis: case of a CML patient with acute appendicitis.

We report on the case of a 24-year-old white man with a history of chronic leukemia treated with unrelated bone marrow transplantation and chemotherapy who was correctly diagnosed with appendicitis rather than typhlitis. The approach to diagnosing an acute abdomen in the leukemic patient is discussed, with particular focus on appendicitis vs. typhlitis. A focused CT scan proved to be instrumental in making the correct diagnosis of appendicitis in our patient. The literature on this topic for the past 30 years is reviewed. The purpose of our report is to demonstrate that despite the recent trend toward diagnosing RLQ pain as typhlitis which requires medical management, there are still instances where it 'really is' appendicitis. Appendicitis, therefore, must always be ruled out in the leukemic patient.

Acute Disease↗
PubMed2004

[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14 patients lacking pretreatment. Therapy resulted in a reduction of CD61(+) megakaryopoiesis. Dwarf megakaryocytes characteristic for this disorder were replaced by large, normally appearing cells of this lineage. Morphometric analysis confirmed the significant decrease in the number of micromegakaryocytes and yielded planimetric parameters in keeping with normalization. Moreover, a fluorescence in-situ hybridization study in five patients of this cohort revealed that before therapy 70% of all myeloid cells exhibited the bcr/abl gene. Regarding megakaryopoiesis about 65% of the micromegakaryocytes displayed positive signals. Following treatment these bcr/abl(+) cell populations decreased significantly while the emerging large megakaryocytes lacked a proper labeling. Because cytogenetic response and reduction of atypical micromegakaryocytes are linked, this feature may be useful to monitor therapeutic efficacy.

Biopsy↗
PubMed1977

Cell mediated lympholysis: CML. a microplate technique requiring few target cells and employing a new method of supernatant collection.

A micro method for the 51Cr release assay is described. Allogeneically induced cytotoxic lymphocytes are generated in micro mixed lymphocyte cultures in the wells of micro plates. Their cytotoxic capacity is assayed by adding 51Cr labelled PHA derived lymphoblasts directly into the micro cultures with no pooling or transfer of the cytotoxic effector cells being required. The 51Cr isotope released into the cell supernatants is collected by inserting a cellulose acetate absorption cartridge into each well. A glass fiber filter attached to the cartridge effectively separates the supernatant from the cellular elements. This system allows the simultaneous collection of the supernatant from 96 wells, and can be used with either adherent or non-adherent target cells.

Cells, Cultured↗
PubMed1981

A simple micromethod for MLC and CML with low numbers of murine lymph node and peripheral blood lymphocytes.

A fast and simple method is described for the mixed lymphocyte culture (MLC) of low numbers of murine lymph node (LN) and peripheral blood lymphocytes (PBL). Cultures were set up with 1 X 10(4) - 4 X 10(4) responder cells in wells of inverted Terasaki plates where the cells settled at the meniscus of a hanging drop. [3H]thymidine incorporation and 51Cr-release from appropriate allogeneic target cells were determined either directly in the same hanging drop or after cell transfer and serial 2-fold dilutions in new Terasaki plates. Replicate measurements were reproducible by both methods. Responder and stimulator cell surface antigens could also be tested by addition of antisera with complement, either at the initiation or at the effector stage of culture. Since culture volumes were only 15 microliter, almost negligible quantities of antisera were required. The method was thus particularly valuable for testing with antisera of limited availability. Examples are given where inclusion of an anti-responder alloantiserum plus complement on day 0 of the MLC eliminated the day 4 cytotoxic response, and where treatment of cytotoxic effector cells with alloantiserum plus complement for 1 h prior to the 51Cr-release assay eliminated the effector cell activity.

Animals↗
PubMed1991

Correlation of M-bcr breakpoint with different chromosomal abnormalities in blast crisis Ph1-positive CML.

The molecular genetics of the Philadelphia (Ph1) chromosome, arising from a reciprocal translocation between chromosomes 9 and 22 and involving the genes abl and bcr, has been well characterized. However, the Ph1 chromosome is usually the sole cytogenetic abnormality during the chronic phase of the disease with additional karyotypic abnormalities arising prior to, or during the onset of the blast or acute phase. We have shown that patients with a breakpoint within the 5' region of the M-bcr of the bcr gene have a different sub-set of chromosomal bands involved in the cytogenetic abnormalities observed during the development of blast crisis than those patients with a 3' breakpoint. This suggests that different mechanisms of progression to blast crisis may be implicated for the subgroups groups of patients.

Blast Crisis↗